Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | ACACA | Q13085 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP7 | P09237 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP13 | P45452 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.33 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | GCK | P35557 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6303523 | 0.83 | MMP2 (0.35) | MMP2MMP7MMP9MMP13P2RX3 | |
| SCHEMBL7116084 | 0.81 | MMP2 (0.37) | RAB9AHSD17B10NPC1ACACBACACA | |
| SCHEMBL6305220 | 0.81 | MMP2 (0.37) | RAB9AHSD17B10NPC1ACACBACACA | |
| SCHEMBL6309902 | 0.81 | MMP2 (0.38) | HSD17B10MMP2MMP7MMP9MMP13 | |
| SCHEMBL6303219 | 0.80 | MMP2 (0.43) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL6305962 | 0.80 | MMP2 (0.54) | NPC1MMP2MMP7MMP9MMP13 | |
| SCHEMBL6309998 | 0.79 | MMP2 (0.37) | RAB9ANPC1MMP2MMP7MMP9 | |
| SCHEMBL6307351 | 0.79 | CHRNA7 (0.36) | RAB9AHSD17B10NPC1CHRNA7EZH2 | |
| SCHEMBL6305852 | 0.79 | MMP2 (0.35) | MMP2MMP7MMP9MMP13EZH2 | |
| SCHEMBL6309450 | 0.79 | NAAA (0.49) | RAB9ANPC1MMP2MMP7MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | claimed |
| US-6852716-B2 | Substituted-aryl compounds for treatment of disease | PFIZER INC (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1480977-A2 | SUBSTITUTED ARYL COMPOUNDS FOR TREATMENT OF DISEASE | PHARMACIA & UPJOHN COMPANY (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | PHARMACIA & UPJOHN COMPANY | 2003-12-25 | — | — | US | disclosed |
| WO-2003070728-A2 | AZABICYCLO-SUBSTITUTED BENZOYLAMIDES AND THIOAMIDES FOR TREATMENT OF CNS-RELATED DISORDERS | PHARMACIA & UPJOHN COMPANY (US) | 2003-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236279-A1 | Substituted-aryl compounds for treatment of disease | NAT1, CYP7A1, CYP7B1 | RAB9A 975/4885HSD17B10 183/4885NPC1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.